Endoscopic band ligation compared to thermal therapy for gastric antral vascular ectasia: A systematic review and meta-analysis

Jean M. Chalhoub¹ | Jalaluddin Umar¹ | Kevin Groudan¹ | Nour Hamadeh² | David J. Desilets¹ | Yesenia Greeff¹

¹Division of Gastroenterology and Hepatology, University of Massachusetts, Springfield, Illinois, USA
²School of Medicine, Indiana University, Indianapolis, Indiana, USA

Correspondence
Yesenia Greeff, Division of Gastroenterology and Hepatology, University of Massachusetts Medical School, Baystate 759 Chestnut Street, S2606, Springfield, MA 01109, USA.
Email: Yesenia.Greeff@baystatehealth.org

Abstract

Background: Gastric antral vascular ectasia is an infrequent cause of gastrointestinal-related blood loss manifesting as iron-deficiency anemia or overt gastrointestinal bleeding, and is associated with increased healthcare burdens. Endoscopic therapy of gastric antral vascular ectasia most commonly involves endoscopic thermal therapy. Endoscopic band ligation has been studied as an alternative therapy with promising results in gastric antral vascular ectasia.

Aims: The primary aim was to compare the efficacy of endoscopic band ligation and endoscopic thermal therapy by argon plasma coagulation for the management of bleeding gastric antral vascular ectasia in terms of the mean post-procedural transfusion requirements and the mean hemoglobin level change. Secondary outcomes included a comparison of the number of sessions needed for cessation of bleeding, the change in transfusion requirements, and the adverse events rate.

Methods: PubMed, Medline, SCOPUS, Google Scholar, and the Cochrane Controlled Trials Register were reviewed. Randomized controlled clinical trials and retrospective studies comparing endoscopic band ligation and endoscopic thermal therapy in bleeding gastric antral vascular ectasia, with a follow-up period of at least 6 months, were included. Statistical analysis was done using Review Manager.

Results: Our search yielded 516 papers. After removing duplicates and studies not fitting the criteria of selection, five studies including 207 patients were selected for analysis. Over a follow-up period of at least 6 months, patients treated with endoscopic band ligation had significantly lower post-procedural transfusion requirements (MD −2.10; 95% confidence interval (−2.42 to −1.77)) and a significantly higher change in the mean hemoglobin with endoscopic band ligation versus endoscopic thermal therapy (MD 0.92; 95% confidence interval [0.39–1.45]). Endoscopic band ligation led to a fewer number of required sessions (MD −1.15; 95% confidence interval [−2.30 to −0.01]) and a more pronounced change in...
transfusion requirements (MD: −3.26; 95% confidence interval [−4.84 to −1.68]). There was no difference in adverse events.

**Conclusion:** Results should be interpreted cautiously due to the limited literature concerning the management of gastric antral vascular ectasia. Compared to endoscopic thermal therapy, endoscopic band ligation for the management of bleeding gastric antral vascular ectasia led to significantly lower transfusion requirements, showed a trend toward more remarkable post-procedural hemoglobin elevation, and a fewer number of procedures. Endoscopic band ligation may improve outcomes and lead to decreased healthcare burden and costs.

**KEYWORDS**
argon plasma coagulation, band ligation, gastric antral vascular ectasia, hemostasis, transfusion

**INTRODUCTION**

Gastric antral vascular ectasia (GAVE) is a pathological condition of the stomach antrum characterized by chronic blood loss. Histologically it is described by ectatic mucosal capillaries in the antrum, which lends a red, streaky appearance to the antral mucosa, and hence is often called "watermelon stomach."

It is associated with multiple chronic medical conditions, including liver, kidney, cardiac, and connective tissue diseases. Whereas it classically manifests as iron-deficiency anemia due to chronic gastrointestinal (GI) blood loss, overt GI bleeding is also sometimes seen, accounting for up to 4% of non-variceal upper GI bleeding.

Management of blood loss secondary to GAVE is primarily endoscopic. Endoscopic thermal therapy (ETT) has been found to be successful, with argon plasma coagulation (APC) and electrocautery with heater probe historically being used for this purpose. APC has been the mainstay treatment of GAVE, but is often limited by recurrence of bleeding. More recently radiofrequency ablation (RFA) and endoscopic band ligation (EBL) have also been performed with promising results. A recent meta-analysis on short-term data showed that RFA has comparable efficacy and tolerability compared to APC and is also effective in cases refractory to APC. However, compared to APC and RFA which only provide superficial mucosal therapy, EBL remains the only modality that involves deep submucosal therapy and is thought to achieve better outcomes. In addition to being safe, EBL requires less endoscopic expertise, is more widely available, and is thought to be cheaper than APC and EBL. No meta-analyses have compared the use of APC and EBL for GAVE management.

Initial case reports documenting the management of GAVE with EBL were published in 2006. In recent years, studies have compared the efficacy of APC versus EBL, including head-to-head, prospective trials. While all studies concluded that EBL is safe and effective in the management of EBL, some studies mention its superiority over ETT in terms of lower transfusion requirements. In fact, in the pediatric population a randomized controlled trial (RCT) showed that, compared to ETT, EBL was associated with fewer sessions, shorter procedure times, less hospitalizations, and a lower rate of GAVE recurrence.

The purpose of this meta-analysis was to identify comparative studies performed in adult patients comparing the efficacy of EBL to that of ETT in the management of GI blood losses related to GAVE.

**METHODS**

**Inclusion and exclusion criteria**

RCTs and retrospective studies comparing EBL and ETT in bleeding GAVE were included in this meta-analysis. All selected studies had a follow-up period of at least 6 months, and compared the change in hemoglobin (Hb) levels after therapy, number of transfusions, the change in transfusion requirement after therapy, and the number of sessions needed for eradication of GAVE. Additionally, the adverse event (AE) rate and the change in hospitalization rate were also evaluated in some included articles. Studies published in abstract form, those that did not include the outcomes of interest, pediatric studies, and those published in a language other than English were not included.

**Search strategy and data sources**

Our search was performed across PubMed, Medline (via OVID), SCOPUS, Google Scholar, and the Cochrane Controlled Trials Register, since initiation until 7 April 2020, without any language restrictions. Search keywords included "gastric antral vascular ectasia," "GAVE," "watermelon stomach," "vascular ectasia of the stomach," "band," and "ligation," as Medical Subject Headings (MeSH) and free text terms. Root variations of these keywords were used in an attempt to improve search outcomes. Since the literature assessing our outcome of interest is limited, we used broad keywords to expand our search outcomes. Additionally, we individually reviewed the references of selected studies to increase our search yield.
Study outcomes

The primary aim was to compare the efficacy of EBL and ETT in terms of the mean post-procedural transfusion requirements and mean Hb level change. Secondary outcomes included a comparison of the number of sessions needed for cessation of bleeding from GAVE, the change in transfusion requirements, as well as the AE rate between both study arms.

Of note, mean Hb change was calculated as the difference between mean Hb levels before and after the procedure in each study arm. The same applied to mean transfusion change.

Study selection

Titles and abstracts of all retrieved articles were reviewed for eligibility for inclusion in our meta-analysis. The investigators collected study characteristics on standardized data sheets after full-text assessment. The senior author addressed discrepancies and made the final decision to whether include or exclude a study. This manuscript follows the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) agreement reporting guidelines and the flow diagram for study selection is summarized in Figure 1.

Data extraction

Our literature search identified 21 studies in English, and so full-text review of these selected studies was performed. Characteristics of the studies—first author, year of publication, study design, number of participants, inclusion criteria, and outcomes of interest—were extracted after identifying all relevant articles.

Statistical analysis

In this meta-analysis, we followed the PRISMA criteria. Analysis was performed using Review Manager 5.3 (RevMan, The Cochrane Collaboration), and odds ratios (ORs) with 95% confidence intervals (CIs) were evaluated for the quantitative analyses of all outcomes. Moreover, means and mean difference (MD) were compared for continuous outcome variables with a 95% CI. The χ² test and I² statistic were used to assess statistical heterogeneity among trials. The I² statistic reflects the percentage of variation between studies due to heterogeneity rather than chance only, with values ranging from 0% (no heterogeneity) to 100% (maximal heterogeneity). An I² > 50% and a p-value of <0.1 for the χ² were considered as markers of significant heterogeneity.

We planned subgroup and sensitivity analysis in advance, and used the random-effects method for conducting this meta-analysis. Subgroup analysis was performed for all primary outcomes based on the following criteria: (a) studies with average sample age ≥60 versus <60, (b) those with a sample size ≥40 patients versus <40 patients, (c) studies in which endoscopies were done at intervals ≤2 weeks versus >2 weeks, and (d) prospective studies versus retrospective studies. The risk of bias among studies was evaluated using Review Manager (RevMan, The Cochrane Collaboration) risk assessment tool for RCTs, and the NewcastleOttawa scale (NOS) for

![Figure 1](image-url) Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow chart of the literature search
RESULTS

Literature search

Our literature search yielded 349 publications. These were screened based on their title and abstract, and 21 articles met our initial inclusion criteria. Of these, 16 articles were excluded, as they were case reports or case series ($n=6$), did not assess our outcome of interest ($n=9$), or were performed in the pediatric population ($n=1$). Therefore, five studies were selected for analysis. A summary of the study selection process is available in Figure 1.

Characteristics of selected trials

Studies included in this meta-analysis had different designs, inclusion criteria, and primary outcomes of interest. Of the selected studies, three were retrospective cohort trials and two were randomized control trials. All studies included patients with GAVE and subsequent evidence of blood loss, excluding those with anemia attributable to other reasons. Cirrhosis was not a prerequisite for inclusion, however, most included patients across the five studies had reported portal hypertension. There was no difference in gender distribution among the study arms in individual studies, however, the average patient age in three studies was $\geq60$ years. Pre-procedure Hb levels were not statistically different between patients in both arms in individual studies. Patient stratification based on Child-Turcotte-Pugh (CTP) scores was not performed in all studies; however, from the available data, there was no statistically significant difference in terms of CTP scores between the EBL and ETT arms in individual studies. None of the included studies compared outcomes in cirrhotic and non-cirrhotic patients. Most included patients undergoing EBL in the five studies were previously treated with ETT. Except for one study where the use of proton pump inhibitors (PPI) was not reported, patients were placed on PPI for at least 1 week after the EBL or ETT. All studies used APC with a 60 W power and argon gas flow of 2 L/min, ablating lesions in a distal to proximal fashion. A thermal probe was applied for ETT in one study only, in two patients as a supplement to APC, and in one patient as the only therapy. Intervals of repeat endoscopy ranged between 1 and 6 weeks depending on the studies, with endoscopies performed as needed in the interim for bleeding. The number of bands placed in a single procedure was not reported for all studies, however, when reported, it ranged from 6-18 bands. The pooled average follow-up period was 10.6 months with a range between 6 and 26 months.

Regarding individual study primary outcomes, all of them aimed at comparing the efficacy of EBL and ETT, however, the definition of efficacy varied between studies. The mean post-procedure number of transfusions, and the number of sessions required to obliterate GAVE were reported in all five studies. Mean Hb levels, mean change in Hb, mean change in transfusions, AE rate, and post-procedure hospitalizations were not assessed by all studies. Reported AEs were all mild including nausea, abdominal distention, and discomfort.

The pooled number of included patients was 207, out of which 93 underwent EBL and 114 received ETT.

Our assessment of the included studies for possible bias using the Review Manager risk assessment tool and NOS, yielded a higher risk of comparability and outcome bias in two of the five studies (Table S1). The two RCTs had a higher risk of performance and detection bias (Figure S6). All non-RCTs had a score of six or more on the NOS, which implies that it is less likely that results of the meta-analysis are explained by bias. Despite the high quality of the studies reflected by the high NOS score, two of the six studies had at least one component of bias, so we performed our sensitivity analysis accordingly. Outcome bias based on adequacy of follow-up was detected in one study. Comparability bias, which is minimized by matching study patients or by adjusting for confounders in data analysis, was evident in two studies. The characteristics of the selected studies are summarized in Table 1.

Primary outcomes

Post-procedure transfusion requirements

All five studies looked at post-procedure transfusion requirements, however, only four could be analyzed, as one study had missing data (standard deviations). Overall, 173 subjects were included in this analysis. Our meta-analysis showed that over a follow-up period of at least 6 months, patients treated with EBL had significantly lower post-procedural transfusion requirements with a mean of 1.9 transfusions compared to 4.60 in those in ETT group, with a mean difference of around two transfusions ($\text{MD}=−2.10; \text{95% CI} [−2.42 to −1.77]$) (Figure 2a). Heterogeneity was not significant with an $I^2$ of 0% and $p$-value of 0.73. Among the subgroup analyses performed, a statistically significant difference between EBL and ETT was only noted in studies with patients of average age $<60$, studies including $\geq40$ patients, and those with a prospective design ($\text{MD}=−2.09; \text{95% CI} [−2.42 to −1.76]$). Regardless of the time interval between endoscopies ($\leq2$ weeks vs. $>2$ weeks), EBL showed statistically significant lower transfusion requirements (Figure S1a). Our sensitivity analysis showed that in studies with a higher risk of bias, patients undergoing EBL required significantly a lower number of post-procedural transfusions compared to those undergoing ETT (Figure S2).
### TABLE 1  Characteristics of selected trials

| Study       | Design     | Inclusion criteria | Exclusion criteria | N                  | Mean patient age Females | EBL (n/N) | ETT (n/N) | PPI after procedure | Prior ETT in EBL patients (n/N) | Repeat EGD | Mean follow-up |
|-------------|------------|--------------------|-------------------|--------------------|---------------------------|-----------|-----------|---------------------|---------------------------------|-------------|-----------------|
| Abdelhalim 2014 | RCT Adults Bleeding GAVE Cirrhosis/portal hypertension | Age <18 years Bleeding not from GAVE | 40/40 | 55.6 57.1 | 11/20 | 10/20 | Yes | N/a | Every 3 weeks until improved 6 months | If bleeding in the interim |
| Elhendawy 2015 | RCT Adults Bleeding GAVE Cirrhosis/portal hypertension | Age <18 years Bleeding not from GAVE | 88/88 | 51.4 53.1 | 25/44 | 29/44 | N/a | 9/44 | Every 2 weeks until improved 6 months | At 6 months |
| Keohane 2013 | Retrospective cohort Adults Bleeding GAVE Cirrhosis/portal hypertension | Age <18 years Bleeding not from GAVE | 23 | N/a | 70.4 75.9 | 6/8 | 11/15 | Yes | 6/8 | N/a | 26 months |
| Sato 2011 | Retrospective cohort Adults Bleeding GAVE Portal hypertension | Age <18 years Bleeding not from GAVE | 34/32 | 68.5 6/12 | 6/12 | 13/22 | Yes | 6/12 | Weekly until improved 15.9 months |
| Wells 2008 | Retrospective cohort Adults Bleeding GAVE | Age <18 years Bleeding not from GAVE | 22/10 | 70.4 75.9 | 4/9 | 8/13 | Yes | 4/9 | Every 4-6 weeks 13 months | If bleeding in the interim If warranted by treating physician |

Abbreviations: EBL, endoscopic band ligation; EGD, esophagogastroduodenoscopy; ETT, endoscopic thermal therapy; GAVE, gastric antral vascular ectasia; PPI, proton pump inhibitors; RCT, randomized controlled trial.
### Post-procedure mean transfusion number

| Study or Subgroup | EBL Mean SD | EBL Total | ETT Mean SD | ETT Total | Weight | Mean difference IV, Random, 95% CI | Mean difference IV, Random, 95% CI |
|-------------------|-------------|-----------|-------------|-----------|--------|-----------------------------------|-----------------------------------|
| Abdelhalim 2014   | 20.1 0.7    | 20        | 2 3 20      | 5.6%      | −1.90  | −3.25 to −0.55                    | −3.25 to −0.55                    |
| Elhendawy 2015    | 2.5 0.7     | 44        | 4 4.6 0.9 44| 93.9%     | −2.10  | −2.44 to −1.76                    | −2.44 to −1.76                    |
| Keohane 2013      | 3.5 6.1     | 8         | 9 317.1 15  | 0.1%      | −5.80  | [15.43, 3.83]                     | [15.43, 3.83]                     |
| Sato 2011         | 2.4 0       | 12        | 2 7 0 22    | 0.2%      | −5.50  | [−13.70, 2.70]                    | [−13.70, 2.70]                    |
| Wells 2008        | 0.9 2       | 9         | 6 414.9 13  | 100.0%    | −3.16  | [−6.32, 0.00]                     | [−6.32, 0.00]                     |
| Total (95% CI)    | 93          | 114       | 100.0%      |           | −2.10  | [−4.24, −1.77]                    | [−4.24, −1.77]                    |

Heterogeneity: Tau² = 0.00; Ch² = 1.31, df = 3 (p = 0.73); I² = 0%
Test for overall effect: z = 12.60 (p < 0.00001)

### Post-procedure transfusion change

\[ \text{Transfusion change} = \text{Transfusion post-procedure} - \text{Transfusion pre-procedure} \]

| Study or Subgroup | EBL Mean SD | EBL Total | ETT Mean SD | ETT Total | Weight | Mean difference IV, Random, 95% CI | Mean difference IV, Random, 95% CI |
|-------------------|-------------|-----------|-------------|-----------|--------|-----------------------------------|-----------------------------------|
| Abdelhalim 2014   | 2.4 1.4     | 20        | 1.4 0.9 20  | 22.8%     | 1.00   | [0.27, 1.73]                      | [0.27, 1.73]                      |
| Elhendawy 2015    | 3.6 0.2     | 44        | 3.1 0.2 44  | 39.9%     | 0.50   | [0.42, 0.58]                      | [0.42, 0.58]                      |
| Keohane 2013      | 3.1 0.6     | 8         | 1.9 0.4 15  | 30.8%     | 1.20   | [0.74, 1.66]                      | [0.74, 1.66]                      |
| Wells 2008        | 2.8 2.5     | 9         | 0.9 1.8 13  | 6.5%      | 1.90   | [−0.00, 3.80]                     | [−0.00, 3.80]                     |
| Total (95% CI)    | 81          | 92        | 100.0%      |           | 0.92   | [0.39, 1.45]                      | [0.39, 1.45]                      |

Heterogeneity: Tau² = 0.18; Ch² = 12.14, df = 3 (p = 0.007); I² = 75%
Test for overall effect: z = 3.41 (p = 0.0006)

FiguRe 2  Forest plot comparing post-procedural (a) transfusion requirements and (b) hemoglobin (Hb) change between EBL and ETT. CI, confidence interval; EBL, endoscopic band ligation; ETT, endoscopic thermal therapy; SD, standard deviation

### Post-procedure Hb change

Hb change was evaluated in four studies, with a total of 173 patients. The analysis showed that patients undergoing EBL had a more pronounced change in Hb after the procedure that was almost 1 gm/dl higher than the change seen with ETT (MD 0.92; 95% CI [0.39–1.45]). The mean postprocedure Hb change in the EBL group was 3.16 compared to 2.22 in the ETT counterpart. Heterogeneity was remarkable with I² of 75% and p-value of 0.007 (Figure 2b).

Subgroup analyses showed statically significant results favoring EBL over ETT, regardless of subgroup stratification (Figure S3). Sensitivity analysis only showed statistically significant outcomes favoring EBL over ETT in studies with a component of bias, while studies with a lower risk of bias did not show any statically significant difference between the two study arms (Figure S4).

### Secondary outcomes

#### Sessions required to obliterate GAVE

All studies evaluated the number of sessions required to obliterate GAVE. A total of 207 patients were included in this analysis. Patients undergoing EBL required less sessions (mean 2.63) to achieve obliteration of GAVE compared to those undergoing ETT (mean 3.83) with a mean difference of −1.15 sessions (MD −1.15; 95% CI [−2.30 to −0.01]; I² 92%, p < 0.001) (Figure 3a). Heterogeneity was remarkable and as a result, sensitivity analysis was performed, revealing a statistically significant difference in the number of sessions required only in studies with a higher risk of bias, while those with a lower risk of bias showed no difference (Figure S5).

#### Post-procedure change in transfusion requirements

The change in transfusion requirements after the procedure was only evaluated in three studies with a total of 80 subjects. The mean change in transfusion requirements for patients in the EBL arm was −6.2 compared to −1.78 for patients in the ETT group. The analysis showed that patients in the EBL arm had a significantly higher change in transfusion requirement, with a mean difference of 3.26 (MD −3.26; 95% CI [−4.84 to −1.68]; I² 19%, p = 0.29), compared to those undergoing ETT (Figure 3b).

#### AE rate

The AE rate was only assessed in three studies which included a total of 133 included patients. The majority of reported AEs were mild and included abdominal pain, distention, nausea, vomiting, and fever.
There was only one reported case of immediate post-procedural bleeding requiring repeat endoscopy. There was a total of eight AEs reported in the EBL group and 10 in the ETT group with no statistical difference between patients in the two arms (OR 0.84; 95% CI [0.31–2.30]; I² 0%; p = 0.40) (Figure 3c).

DISCUSSION

This systematic review and meta-analysis suggests that over a follow-up period of at least 6 months, the use of EBL compared to ETT for the management of GAVE associated with GI blood loss and anemia led to an average of two fewer blood transfusions with a remarkable change in transfusion requirements, a trend towards a greater change in post-procedural Hb and a lower number of required sessions to obliterate GAVE. There was no difference in AEs between the two groups.

Five studies were included and the metrics used to compare efficacy differed between them. The number of post-procedure transfusions required, the change in transfusion requirements, Hb levels after the procedure, change in Hb levels, and number of sessions required were the most commonly evaluated criteria to define efficacy. Only two studies evaluated interval bleeding between procedures and GAVE recurrence. Given (a) the lack of a universally used efficacy metric, (b) the absence of a statistically significant difference in the preprocedural transfusion requirements between EBL...
and ETT in each individual study, and (c) since the number of post-procedure transfusions and the change in Hb pre- and post-procedure were mentioned in all studies, we opted to use the latter two metrics (post-procedural transfusions and change in Hb) to reflect the efficacy of the procedure. In addition, we reviewed the literature about GI angiodysplasias which are vascular malformations like GAVE, that similarly result in slow occult bleeding. Most studies used transfusion requirements and the change in Hb levels as markers to assess interventional efficacy.18

We postulated that the number of sessions required to obliterate GAVE was not an optimal criterion to assess efficacy. The first reason being that included studies had variable time intervals between endoscopies, leading to the possibility of more GAVE recurrence and bleeding in studies with longer intervals. Another reason is the potential for more interventions required to eradicate GAVE in studies with a shorter interval between procedures. In retrospect, and after reviewing our results, we think that the varying intervals between endoscopies in different studies did not impact the primary outcomes and the number of sessions required as the ranges of results were not significantly large.

Moreover, procedural methods between study groups could be expected to vary, making it difficult to provide an objective assessment of efficacy. Although four studies reported post-procedure Hb levels, we postulated that the absolute value of the Hb was less useful as a marker of efficacy. Rather, we thought that the change in Hb from pre-to post-procedure (Hb_change = Hb_post-procedure − Hb_pre-procedure) was a more realistic measure of efficacy.

With respect to post-procedure transfusions requirements, subgroup analysis only showed a statistically significant difference between EBL and ETT in studies with an average age <60 years, studies with ≥40 patients, and those with a prospective design. Of note, and by coincidence, the same two prospective studies happened to include ≥40 patients with average age <60.6,15 Among the three remaining retrospective, small-sized studies, any difference between the two study arms was likely limited by the small number of pooled patients. In addition, sensitivity analysis showed a difference between EBL and ETT only in studies with a higher risk of bias. However, we would like to note that this was limited by the available literature and by the fact that the two available RCTs were non-blinded. In addition, in the lower risk of bias group, only two small studies were included, and the analysis was effectively performed on one study as the other one had non-estimable outcomes due to the lack of reported standard deviations.

Regarding post-procedure Hb change and the number of sessions required, the analysis was limited by the remarkable heterogeneity, which is likely secondary to the difference in methods between the studies. This assumption was also supported by the sensitivity analysis showing that only studies with a higher risk of bias favored EBL in terms of a more remarkable Hb change and a lower number of sessions. Unfortunately, due to the scarce literature, both heterogeneity and the potentially higher risk of bias in included studies remained a limiting factor of this analysis.

As for the difference in transfusion requirements before and after the procedure, the data is limited by the small number of included patients, but the results suggest a decrease in the number of transfusions needed after EBL versus ETT.

This is the first systematic review and meta-analysis evaluating five head-to-head trials comparing EBL and ETT in GAVE, comprising 207 patients followed for at least 6 months. In the absence of large, well designed RCTs comparing the efficacy of both techniques, our study provides a pooled analysis of the currently available data. In fact, the study results are in line with the currently available RCTs, suggesting that the fairly under-utilized EBL procedure may be more effective than ETT, at least in terms of the post-procedural transfusion requirements and possibly the number of sessions needed for complete eradication of the GAVE. Unfortunately, the limited literature and the lack of large prospective trials have limited the use of EBL in the management of GAVE for salvage therapy in refractory GAVE. In our experience, it seems that ETT and specifically APC are more commonly used despite being more expensive, not as widely available, and offering limited superficial therapy. Theoretically, EBL is thought to have a deeper effect involving the submucosa, leading to fibrosis and potentially longer effects with less recurrence.8

Nonetheless, as previously mentioned, this meta-analysis is limited by the small number of pooled patients. In addition, our analyses were limited by the different methodologies, reflected with high heterogeneity, and also by the difference in the reported outcomes between studies. In fact, the occurrence and timing of bleeding in the interval between procedures would have been more objective outcomes of interest to compare efficacy, but those were not reported in any adult study. Additionally, individual studies lacked a comparison of outcomes between cirrhotic versus non-cirrhotic patients, and did not stratify patients according to prior therapy for GAVE (i.e. treatment naïve, exposed (prior ETT), or refractory to ETT). Also, the included studies are limited by a short follow-up period. The durability of the response over a long period would be another potentially significant marker of efficacy, especially in light of a recent study reporting up to 44% recurrence of GAVE within 2 years of clinical response to therapy with EBL.19

In conclusion, EBL appears to be both safe and effective in the management of GAVE-related blood loss. The limited literature suggests that compared to ETT, the use of EBL was associated with significantly lower transfusion requirements, and showed a trend towards more encouraging post-procedural Hb changes and lower number of procedures required to obliterate GAVE. This meta-analysis suggests that the use of EBL in the management of bleeding GAVE has the potential to reduce the healthcare burdens and costs. Those results should be interpreted cautiously until well-designed RCTs emerge to further our understanding of the short- and long-term efficacy of EBL in the management of GAVE.

ACKNOWLEDGMENTS

The following author contributions were made: Jean M. Chalhoub: literature review, study selection, data collection, statistical analysis,
drafting of the manuscript; Jalaluddin Umar: literature review, study selection, data collection, statistical analysis, drafting of the manuscript; Kevin Groudan: literature review, drafting of the manuscript, regulatory administration, critical review of the manuscript; Nour Hamadeh: data interpretation, critical review of the manuscript; David J. Desilets: data interpretation, critical review of the manuscript; Yesenia Greeff: study idea, concept, design and supervision, data interpretation, review of the literature, drafting of the manuscript, guarantor of the study. All authors approved the submitted version of the manuscript. The authors received no financial support for the research, authorship, and/or publication of this article.

CONFLICT OF INTEREST
The authors have no conflicts of interest to declare.

REFERENCES
1. Payen JL, Calès P, Voigt JJ, et al. Severe portal hypertensive gastropathy and antral vascular ectasia are distinct entities in patients with cirrhosis. Gastroenterology. 1995;108:138–44.
2. Patwardhan VR, Cardenas A. Review article: the management of portal hypertensive gastropathy and gastric antral vascular ectasia in cirrhosis. Aliment Pharmacol Ther. 2014;40:354–62.
3. Dulai GS, Jensen DM, Kovacs TOG, et al. Endoscopic treatment outcomes in watermelon stomach patients with and without portal hypertension. Endoscopy. 2004;36:68–72.
4. Wells CD, Harrison ME, Gurudu SR, et al. Treatment of gastric antral vascular ectasia (watermelon stomach) with endoscopic band ligation. Gastrointest Endosc. 2008;68:231–6.
5. Jana T, Thosani N, Fallon MB, et al. Radiofrequency ablation for treatment of refractory gastric antral vascular ectasia (with video). Endosc Int Open. 2015;3:E125–E127.
6. Elhendawy M, Mosaad S, Alkhalawany W, et al. Randomized controlled study of endoscopic band ligation and argon plasma coagulation in the treatment of gastric antral and fundal vascular ectasia. United European Gastroenterol J. 2016;4:423–8.
7. McCarty TR, Rustagi T. Comparative effectiveness and safety of radiofrequency ablation versus argon plasma coagulation for treatment of gastric antral vascular ectasia: a systematic review and meta-analysis. J Clin Gastroenterol. 2019;53:599–606.
8. Tantau M, Crisan D. Is endoscopic band ligation the gold standard for gastric antral vascular ectasia? Endosc Int Open. 2019;7: E1630–E1631.
9. St Romain P, Boyd A, Zheng J, et al. Radiofrequency ablation (RFA) vs. argon plasma coagulation (APC) for the management of gastric antral vascular ectasia (GAVE) in patients with and without cirrhosis: results from a retrospective analysis of a large cohort of patients treated at a single center. Endosc Int Open. 2018;6:E266–E270.
10. Sinha SK, Udawat HP, Varma S, et al. Watermelon stomach treated with endoscopic band ligation. Gastrointest Endosc. 2006;64: 1028–31.
11. Kumar R, Mohindra S, Pruthi HS. Endoscopic band ligation: a novel therapy for bleeding gastric antral vascular ectasia. Endoscopy. 2007;39:E56–E57.
12. Ghozrial C, Rabea M, Mohsen N, et al. Gastric antral vascular ectasia in portal hypertensive children: endoscopic band ligation versus argon plasma coagulation. J Pediatr Surg. 2019;54:1691–5.
13. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in metaanalyses. Ottawa: The Ottawa Health Research Institute.
14. Mueller KF, Meerpohl JJ, Briel M, et al. Methods for detecting, quantifying, and adjusting for dissemination bias in meta-analysis are described. J Clin Epidemiol. 2016;80:25–33.
15. Abdelhalim H, Mostafa I, Abdelbary MS, et al. Endoscopic band ligation versus argon plasma coagulation for the treatment of gastric antral vascular ectasia in Egyptian patients with liver cirrhosis. World J Med Sci. 2014;10:357–56.
16. Keohane J, Berro W, Harewood GC, et al. Band ligation of gastric antral vascular ectasia is a safe and effective endoscopic treatment. Dig Endosc. 2013;25:392–6.
17. Sato T, Yamazaki K, Akaike J. Endoscopic band ligation versus argon plasma coagulation for gastric antral vascular ectasia associated with liver diseases. Dig Endosc. 2012;24:237–42.
18. Becq A, Rahmi G, Perrod G, et al. Hemorrhagic angiodysplasia of the digestive tract: Pathogenesis, diagnosis, and management. Gastrointest Endosc. 2017;86:792–806.
19. Eccles J, Falk V, Montano-Loza AJ, et al. Long-term follow-up in patients with gastric antral vascular ectasia (GAVE) after treatment with endoscopic band ligation (EBL). Endosc Int Open. 2019;07: E1624–E1629.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Chalhoub JM, Umar J, Groudan K, Hamadeh N, Desilets DJ, Greeff Y. Endoscopic band ligation compared to thermal therapy for gastric antral vascular ectasia: A systematic review and meta-analysis. United European Gastroenterol J. 2021;9:150–158. https://doi.org/10.1177/2050640620975243